Rheumatology Medical News about Arthritis, Rheumatoid Certolizumab Pegol

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/10/09

Duggan ST et al. – Certolizumab pegol is a PEGylated humanized Fab? monoclonal antibody that targets and neutralizes both membrane–bound and soluble tumor necrosis factor (TNF)–alpha, preventing inflammation and consequently the destruction of cartilage and bone. Certolizumab pegol has a relatively long elimination half–life of ?2 weeks, allowing subcutaneous administration once every 2 or 4 weeks...In patients with active rheumatoid arthritis who had previously failed to respond to treatment with >=1 disease–modifying anti–rheumatic drug, certolizumab pegol 400 mg every 4 weeks as monotherapy effectively improved ACR responses at all measured timepoints up to 24 weeks, according to data from the randomized, phase III FAST4WARD trial. Certolizumab pegol was generally well tolerated in combination with methotrexate or as monotherapy in phase III trials in patients with rheumatoid arthritis, with most adverse events being of mild to moderate intensity. Infections were the most frequently reported adverse events.

<< Previous
Synergistic chondroprotective effects of curcumin and resveratrol...

Next >>
Effect of Transdermal Teriparatide Administration on Bone Mineral...

Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis
Arthritis Care and Research, 11/02/09 Relevance Score: 88%

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: Results from the RAPID 1 randomized controlled trial
Arthritis Research & Therapy, 11/16/09 Relevance Score: 87%

Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09 Relevance Score: 71%

Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09 Relevance Score: 70%

Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09 Relevance Score: 69%